Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Scott J. Antonia, Ani Balmanoukian, Julie Brahmer, Sai Hong I. Ou, Matthew D. Hellmann, Sang We Kim, Myung Ju Ahn, Dong Wan Kim, Martin Gutierrez, Stephen V. Liu, Patrick Schöffski, Dirk Jäger, Rahima Jamal, Guy Jerusalem, Jose Lutzky, John Nemunaitis, Luana Calabrò, Jared Weiss, Shirish Gadgeel, Jaishree BhoslePaolo A. Ascierto, Marlon C. Rebelatto, Rajesh Narwal, Meina Liang, Feng Xiao, Joyce Antal, Shaad Abdullah, Natasha Angra, Ashok K. Gupta, Samir N. Khleif, Neil H. Segal

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Fingerprint

Dive into the research topics of 'Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC'. Together they form a unique fingerprint.

Medicine & Life Sciences